File Download
Patent History
- ApplicationPC T/CN2007002938 2007-10-12
- PublicationWO 2008046307 2008-04-24
Patent Family
- AU 2003271510 (A1) 2004-05-04
- CN 1723029 (A) 2006-01-18
- EP 1562616 (A2) 2005-08-17
- JP 2006503109 (A) 2006-01-26
- JP 4786341 (B2) 2011-10-05
- US 2004126434 (A1) 2004-07-01
- US 7521071 (B2) 2009-04-21
- US 2008085931 (A1) 2008-04-10
- US 2008089949 (A1) 2008-04-17
- US 2008089951 (A1) 2008-04-17
- US 2008166425 (A1) 2008-07-10
- WO 2004032822 (A2) 2004-04-22
- WO 2008046299 (A1) 2008-04-24
- WO 2008046307 (A1) 2008-04-24
Supplementary
-
Citations:
- Appears in Collections:
published patent: METHOD FOR INHIBITING CANCER USING ARSENIC TRIOXIDE
Title | METHOD FOR INHIBITING CANCER USING ARSENIC TRIOXIDE |
---|---|
Priority Date | 2006-10-13 US 11/549347 |
Inventors | |
Issue Date | 2008 |
Citation | WO Published patent application WO 2008046307. World Intellectual Property Organization (WIPO), PatentScope, 2008 How to Cite? |
Abstract | The invention provides a method for treating cancers that are dependent on cyclin Dl for proliferation, survival, metastasis and differentiation, involving administering a composition containing an effective amount of arsenic trioxide to an affected patient. The arsenic trioxide can be administered orally, for example, as a solution, suspension, syrup, emulsion, tablet, or capsule. The composition can also contain one or more pharmaceutically acceptable carriers and/or excipients. |
Persistent Identifier | http://hdl.handle.net/10722/177122 |
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2012-11-30T08:39:11Z | - |
dc.date.available | 2012-11-30T08:39:11Z | - |
dc.date.issued | 2008 | - |
dc.identifier.citation | WO Published patent application WO 2008046307. World Intellectual Property Organization (WIPO), PatentScope, 2008 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/177122 | - |
dc.description.abstract | The invention provides a method for treating cancers that are dependent on cyclin Dl for proliferation, survival, metastasis and differentiation, involving administering a composition containing an effective amount of arsenic trioxide to an affected patient. The arsenic trioxide can be administered orally, for example, as a solution, suspension, syrup, emulsion, tablet, or capsule. The composition can also contain one or more pharmaceutically acceptable carriers and/or excipients. | en_HK |
dc.title | METHOD FOR INHIBITING CANCER USING ARSENIC TRIOXIDE | en_HK |
dc.type | Patent | en_US |
dc.description.nature | published_or_final_version | en_US |
dc.contributor.inventor | Kwong, YL | en_HK |
patents.identifier.application | PC T/CN2007002938 | en_HK |
patents.description.assignee | UNIV HONG KONG [CN]; KWONG YOKLAM [CN] | en_HK |
patents.description.country | World Intellectual Property Organization (WIPO) | en_HK |
patents.date.publication | 2008-04-24 | en_HK |
patents.date.application | 2007-10-12 | en_HK |
patents.date.priority | 2006-10-13 US 11/549347 | en_HK |
patents.description.cc | WO | en_HK |
patents.identifier.publication | WO 2008046307 | en_HK |
patents.relation.family | AU 2003271510 (A1) 2004-05-04 | en_HK |
patents.relation.family | CN 1723029 (A) 2006-01-18 | en_HK |
patents.relation.family | EP 1562616 (A2) 2005-08-17 | en_HK |
patents.relation.family | JP 2006503109 (A) 2006-01-26 | en_HK |
patents.relation.family | JP 4786341 (B2) 2011-10-05 | en_HK |
patents.relation.family | US 2004126434 (A1) 2004-07-01 | en_HK |
patents.relation.family | US 7521071 (B2) 2009-04-21 | en_HK |
patents.relation.family | US 2008085931 (A1) 2008-04-10 | en_HK |
patents.relation.family | US 2008089949 (A1) 2008-04-17 | en_HK |
patents.relation.family | US 2008089951 (A1) 2008-04-17 | en_HK |
patents.relation.family | US 2008166425 (A1) 2008-07-10 | en_HK |
patents.relation.family | WO 2004032822 (A2) 2004-04-22 | en_HK |
patents.relation.family | WO 2008046299 (A1) 2008-04-24 | en_HK |
patents.relation.family | WO 2008046307 (A1) 2008-04-24 | en_HK |
patents.description.kind | A1 | en_HK |
patents.type | Patent_published | en_HK |